Year All 2026 2025 2024 2023 2022 2021 2020 Oct 01, 2026 Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI Sep 30, 2026 Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer Sep 30, 2026 Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 Sep 10, 2026 Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors Sep 01, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 26, 2026 Candel Therapeutics to Present at September Investor Conferences Aug 13, 2026 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Aug 03, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2026 Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 Jul 29, 2026 Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
Oct 01, 2026 Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
Sep 30, 2026 Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
Sep 30, 2026 Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
Aug 13, 2026 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Aug 03, 2026 Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
Jul 29, 2026 Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
